venBio Partners LLC Long-Term Concentrated

CIK: 0001776382 · Show all filings

Period: Q3 2023 (← Previous) (Next →)

Filing Date: Nov 14, 2023

Total Value ($000): $352,655 (100.0% shares, 0.0% debt)

Holdings (8)

— RAYZEBIO INC 32.5%

Value ($000) $114,511 Shares 5,158,162 Est. Cost $22.20 Unrealized —

PHVS PHARVARIS N V 25.2%

Value ($000) $89,004 Shares 4,264,672 Est. Cost $21.29 Unrealized -13.4%

ALXO ALX ONCOLOGY HLDGS INC 13.2%

Value ($000) $46,560 Shares 9,699,925 Est. Cost $39.31 Unrealized -86.2%

— ACELYRIN INC 11.1%

Value ($000) $39,180 Shares 3,852,470 Est. Cost $20.90 Unrealized —

HRMY HARMONY BIOSCIENCES HLDGS IN 9.6%

Value ($000) $33,930 Shares 1,035,396 Est. Cost $36.46 Unrealized -4.8%

VTYX VENTYX BIOSCIENCES INC 7.5%

Value ($000) $26,353 Shares 758,800 Est. Cost $25.84 Unrealized +33.8%

— ELEVATION ONCOLOGY INC 0.5%

Value ($000) $1,931 Shares 2,914,255 Est. Cost $9.24 Unrealized —

— IMPEL PHARMACEUTICALS INC 0.3%

Value ($000) $1,187 Shares 2,759,791 Est. Cost $8.85 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	RAYZEBIO INC	5,158,162	$114,511	32.5%	$22.20	—	COM	75525N107
PHVS	PHARVARIS N V	4,264,672	$89,004	25.2%	$21.29	-13.4%	COM	N69605108
ALXO	ALX ONCOLOGY HLDGS INC	9,699,925	$46,560	13.2%	$39.31	-86.2%	COM	00166B105
—	ACELYRIN INC	3,852,470	$39,180	11.1%	$20.90	—	COM	00445A100
HRMY	HARMONY BIOSCIENCES HLDGS IN	1,035,396	$33,930	9.6%	$36.46	-4.8%	COM	413197104
VTYX	VENTYX BIOSCIENCES INC	758,800	$26,353	7.5%	$25.84	+33.8%	COM	92332V107
—	ELEVATION ONCOLOGY INC	2,914,255	$1,931	0.5%	$9.24	—	COM	28623U101
—	IMPEL PHARMACEUTICALS INC	2,759,791	$1,187	0.3%	$8.85	—	COM	45258K109